金域医学
(603882)
| 流通市值：156.35亿 | | | 总市值：157.42亿 |
| 流通股本：4.60亿 | | | 总股本：4.63亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,618,852,446.76 | 3,880,906,151.11 | 1,841,260,736.25 | 8,539,627,901.45 |
| 营业收入 | 5,618,852,446.76 | 3,880,906,151.11 | 1,841,260,736.25 | 8,539,627,901.45 |
| 二、营业总成本 | 5,117,588,587.38 | 3,506,295,279.47 | 1,739,097,569.9 | 7,635,230,948.34 |
| 营业成本 | 3,643,595,996.75 | 2,531,982,051.8 | 1,250,450,786.63 | 5,424,536,307.38 |
| 税金及附加 | 11,588,847.08 | 7,851,677 | 4,087,848.46 | 14,912,450.61 |
| 销售费用 | 677,896,671.99 | 453,413,287.27 | 231,582,425.82 | 1,015,089,926.04 |
| 管理费用 | 483,109,316.58 | 316,142,511.94 | 161,165,342.69 | 714,607,304.4 |
| 研发费用 | 302,366,808.51 | 196,771,885.67 | 92,123,715.26 | 467,138,909.59 |
| 财务费用 | -969,053.53 | 133,865.79 | -312,548.96 | -1,053,949.68 |
| 其中:利息费用 | 14,154,937.35 | 9,325,555.66 | 4,910,179.27 | 20,390,840.42 |
| 其中:利息收入 | 16,887,190.64 | 10,607,997.68 | 5,799,739.12 | 25,388,098.31 |
| 加:投资收益 | -5,122,643.98 | -1,821,241.47 | -2,380,675.99 | 262,966,999.25 |
| 资产处置收益 | 4,659,777.47 | 3,975,726.92 | 3,291,258.06 | 2,200,534.74 |
| 资产减值损失(新) | 40,419.96 | 58,054.5 | -242,874.19 | 519,046.86 |
| 信用减值损失(新) | -420,559,824.32 | -295,987,584.95 | -139,495,232.14 | -488,536,950.12 |
| 其他收益 | 29,929,734.86 | 21,265,390.69 | 11,643,109.08 | 78,215,490.36 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 110,211,323.37 | 102,101,217.33 | -25,021,248.83 | 759,762,074.2 |
| 加:营业外收入 | 1,789,837.13 | 1,304,047.16 | 801,067.08 | 3,782,598.02 |
| 减:营业外支出 | 16,060,040.36 | 6,527,927.9 | 2,585,760.1 | 23,256,127.9 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 95,941,120.14 | 96,877,336.59 | -26,805,941.85 | 740,288,544.32 |
| 减:所得税费用 | 12,073,258.49 | 13,615,407.7 | -386,528.46 | 103,380,033.29 |
| 六、净利润 | 83,867,861.65 | 83,261,928.89 | -26,419,413.39 | 636,908,511.03 |
| 持续经营净利润 | 83,867,861.65 | 83,261,928.89 | -26,419,413.39 | 636,908,511.03 |
| 归属于母公司股东的净利润 | 93,838,992.07 | 89,650,203.48 | -18,637,084.22 | 643,382,149.84 |
| 少数股东损益 | -9,971,130.42 | -6,388,274.59 | -7,782,329.17 | -6,473,638.81 |
| (一)基本每股收益 | 0.2 | 0.19 | -0.04 | 1.38 |
| (二)稀释每股收益 | 0.2 | 0.19 | -0.04 | 1.38 |
| 八、其他综合收益 | -3,044,204.15 | 3,426,846.19 | 80,537.6 | 7,990,400.18 |
| 归属于母公司股东的其他综合收益 | -3,044,204.15 | 3,426,846.19 | 80,537.6 | 7,990,400.18 |
| 九、综合收益总额 | 80,823,657.5 | 86,688,775.08 | -26,338,875.79 | 644,898,911.21 |
| 归属于母公司股东的综合收益总额 | 90,794,787.92 | 93,077,049.67 | -18,556,546.62 | 651,372,550.02 |
| 归属于少数股东的综合收益总额 | -9,971,130.42 | -6,388,274.59 | -7,782,329.17 | -6,473,638.81 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |